South Africa on Thursday awarded the two-year contract to 12 domestic and international firms to supply life-prolonging drugs to treat its biggest single health problem.
Aspen Pharmacare, Africa’s largest generic drugs maker, has won 20,6% of the contract, while smaller rival Adcock Ingram was awarded 14%, the health department said in a statement.
Cipla Medpro, the drugmaker in which India’s Cipla has offered to buy a majority stake, was awarded 9%, the government said.
A Cipla Medpro spokesman said its share of the contract rises to 24,5% when including wholly owned unit Medpro Pharmaceutica.
Medpro Pharmaceutica, which won 15,5% of the contract, tendered a separate bid from that of its parent.
Medpro Pharmaceutica will import the drugs from India, while Cipla Medpro is a local manufacturer, the spokesman said.
Cipla Medpro has a longstanding supply deal with India’s Cipla.
That deal was spearheaded by former Cipla Medpro Chief Executive Jerome Smith, who quit last month following charges of gross misconduct for approving pay rises and bonuses for himself without board approval.
($1 = 8,7660 South African rand)